Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate plus docetaxel versus docetaxel alone in hormone-refractory prostate cancer
NL-OMON22637Phase 3Active, not recruiting
- Sponsor
- Not applicable
- Start
- Dec 2003
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in castration-resistant prostate cancer (CRPC) comparing Docetaxel + prednisone with Docetaxel + risedronate + prednisone (2 arms). Primary endpoints: Objective PSA response and Time to progression. Started Dec 2003; status: active, not recruiting.
02
Drugs
risedronatedocetaxelprednisone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON22637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22637.